Clinical Trial Detail

NCT ID NCT01639508
Title Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Cabozantinib

Age Groups: adult senior

Additional content available in CKB BOOST